NasdaqGS:CAIBiotechs
Caris Life Sciences (CAI) Q4 Profitability Turnaround Tests Skeptical Earnings Narratives
Caris Life Sciences (CAI) closed out FY 2025 with Q4 revenue of US$292.9 million and basic EPS of US$0.29, alongside net income of US$82.0 million. Over the past six reported quarters, the company has seen revenue move from US$129.9 million in Q4 2024 to US$292.9 million in Q4 2025. Over the same period, basic EPS has ranged from a loss of US$7.97 in Q2 2025 to a profit of US$0.29 in the latest quarter. This sets up a story in which improving margins and the quality of those earnings are...